Literature DB >> 20923250

Plasma anti-Xa monitoring for low-molecular-weight heparins in patients with chronic kidney disease.

Maurizio Gallieni, Alma Martini, Antonio Granata, Maria Fusaro.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20923250     DOI： 10.2165/11534810-000000000-00000

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  11 in total

1.  Low-molecular-weight heparins should be used with caution in patients with chronic kidney disease.

Authors:  Maurizio Gallieni; Mario Cozzolino; Chiara Ronga; Diego Brancaccio
Journal:  Nat Clin Pract Nephrol       Date:  2008-07-08

2.  Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency.

Authors:  A T Gerlach; K K Pickworth; S K Seth; S B Tanna; J F Barnes
Journal:  Pharmacotherapy       Date:  2000-07       Impact factor: 4.705

3.  Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.

Authors:  Wendy Lim; Francesco Dentali; John W Eikelboom; Mark A Crowther
Journal:  Ann Intern Med       Date:  2006-05-02       Impact factor: 25.391

4.  Routine plasma anti-Xa monitoring is required for low-molecular-weight heparins.

Authors:  Hesham S Al-Sallami; Michael A Barras; Bruce Green; Stephen B Duffull
Journal:  Clin Pharmacokinet       Date:  2010-09       Impact factor: 6.447

5.  Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis.

Authors:  Benjamin Guillet; Nicolas Simon; Jérôme José Sampol; Anne-Marie Lorec-Penet; Henri Portugal; Yvon Berland; Bertrand Dussol; Philippe Brunet
Journal:  Nephrol Dial Transplant       Date:  2003-11       Impact factor: 5.992

6.  Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations.

Authors:  Lesley A Stevens; Thomas D Nolin; Michelle M Richardson; Harold I Feldman; Julia B Lewis; Roger Rodby; Raymond Townsend; Aghogho Okparavero; Yaping Lucy Zhang; Christopher H Schmid; Andrew S Levey
Journal:  Am J Kidney Dis       Date:  2009-05-17       Impact factor: 8.860

7.  Individualized compared with conventional dosing of enoxaparin.

Authors:  M A Barras; S B Duffull; J J Atherton; B Green
Journal:  Clin Pharmacol Ther       Date:  2007-10-10       Impact factor: 6.875

Review 8.  Structure-activity relationships of low molecular weight heparins expose to the risk of achieving inappropriate targets in patients with renal failure.

Authors:  Piero Stratta; Eirini Karvela; Caterina Canavese; Marco Quaglia; Elisa Lazzarich; Roberta Fenoglio; Patrizia Pergolini; Giorgio Bellomo; Tiziana Cena; Corrado Magnani
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

9.  A new equation to estimate glomerular filtration rate.

Authors:  Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391

10.  Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease.

Authors:  Vasim Farooq; Janet Hegarty; Thangavelu Chandrasekar; Elizabeth H Lamerton; Sandip Mitra; John B Houghton; Philip A Kalra; Stephen Waldek; Donal J O'Donoghue; Grahame N Wood
Journal:  Am J Kidney Dis       Date:  2004-03       Impact factor: 8.860
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.